- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Feladilimab (GSK3359609) is a humanized IgG4 anti-ICOS monoclonal antibody that was developed for immuno-oncology potential. It was withdrawn from development in mid-2021 following a failure to demonstrate efficacy in a Phase 2 trial in patients with non-small cell lung cancer.
Peptide sequence analysis suggests that feladilimab is derived from clone H2L5 hIgG4PE in GSK patent WO2016120789 . Feladilimab competes with ICOS ligand for binding to ICOS.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Feladilimab (GSK3359609) was progressed to clinical evaluation in solid tumours, but due to lack of efficacy, development was discontinued in mid-2021.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02723955||Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)||Phase 1 Interventional||GlaxoSmithKline|
|NCT04128696||Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Phase 2/Phase 3 Interventional||GlaxoSmithKline|
|NCT04428333||Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Phase 2/Phase 3 Interventional||GlaxoSmithKline|
|NCT03739710||Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Non-small Cell Lung Cancer (NSCLC)||Phase 1/Phase 2 Interventional||GlaxoSmithKline|